Literature DB >> 28157386

Fifty Years of Research in ARDS. The Epidemiology of Acute Respiratory Distress Syndrome. A 50th Birthday Review.

Tài Pham1,2, Gordon D Rubenfeld1,3.   

Abstract

Since its first description 50 years ago, no other intensive care syndrome has been as extensively studied as acute respiratory distress syndrome (ARDS). Despite this extensive body of research, many basic epidemiologic questions remain unsolved. The lack of gold standard tests jeopardizes accurate diagnosis and translational research. Wide variation in the population incidence has been reported, making even simple estimates of the burden of disease problematic. Despite these limitations, there has been an increase in the understanding of pathophysiology and important risk factors both for the development of ARDS and for important patient-centered outcomes like mortality. In this Critical Care Perspective, we discuss the historical context of ARDS description and attempts at its definition. We highlight the epidemiologic challenges of studying ARDS, as well as other intensive care syndromes, and propose solutions to address them. We update the current knowledge of ARDS trends in incidence and mortality, risk factors, and recently described endotypes.

Entities:  

Mesh:

Year:  2017        PMID: 28157386     DOI: 10.1164/rccm.201609-1773CP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  69 in total

1.  Acute respiratory distress syndrome without identifiable risk factors: A secondary analysis of the ARDS network trials.

Authors:  John S Harrington; Edward J Schenck; Clara Oromendia; Augustine M K Choi; Ilias I Siempos
Journal:  J Crit Care       Date:  2018-06-02       Impact factor: 3.425

2.  Patients with acute respiratory distress syndrome exhibit increased stromelysin1 activity in the blood samples.

Authors:  Sandeep Artham; Arti Verma; Andrea Sikora Newsome; Payaningal R Somanath
Journal:  Cytokine       Date:  2020-04-06       Impact factor: 3.861

Review 3.  Definition and epidemiology of acute respiratory distress syndrome.

Authors:  Emanuele Rezoagli; Roberto Fumagalli; Giacomo Bellani
Journal:  Ann Transl Med       Date:  2017-07

4.  Risk Stratification Using Oxygenation in the First 24 Hours of Pediatric Acute Respiratory Distress Syndrome.

Authors:  Nadir Yehya; Neal J Thomas; Robinder G Khemani
Journal:  Crit Care Med       Date:  2018-04       Impact factor: 7.598

5.  Haptoglobin-2 variant increases susceptibility to acute respiratory distress syndrome during sepsis.

Authors:  V Eric Kerchberger; Julie A Bastarache; Ciara M Shaver; Hiromasa Nagata; J Brennan McNeil; Stuart R Landstreet; Nathan D Putz; Wen-Kuang Yu; Jordan Jesse; Nancy E Wickersham; Tatiana N Sidorova; David R Janz; Chirag R Parikh; Edward D Siew; Lorraine B Ware
Journal:  JCI Insight       Date:  2019-11-01

6.  KIAA0317 regulates pulmonary inflammation through SOCS2 degradation.

Authors:  Travis B Lear; Alison C McKelvey; John W Evankovich; Shristi Rajbhandari; Tiffany A Coon; Sarah R Dunn; James D Londino; Bryan J McVerry; Yingze Zhang; Eleanor Valenzi; Christine L Burton; Rachael Gordon; Sebastien Gingras; Karina C Lockwood; Michael J Jurczak; Robert Lafyatis; Mark J Shlomchik; Yuan Liu; Bill B Chen
Journal:  JCI Insight       Date:  2019-10-03

Review 7.  Extracorporeal membrane oxygenation as rescue therapy for severe hypoxemic respiratory failure.

Authors:  Bhoumesh Patel; Subhasis Chatterjee; Seanna Davignon; J Patrick Herlihy
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

8.  Pharmacological modulation of C-X-C motif chemokine receptor 4 influences development of acute respiratory distress syndrome after lung ischaemia-reperfusion injury.

Authors:  Sean P Nassoiy; Favin S Babu; Heather M LaPorte; Matthias Majetschak
Journal:  Clin Exp Pharmacol Physiol       Date:  2017-09-20       Impact factor: 2.557

Review 9.  Amicus or Adversary Revisited: Platelets in Acute Lung Injury and Acute Respiratory Distress Syndrome.

Authors:  Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 6.914

10.  Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials.

Authors:  Edward J Schenck; Clara Oromendia; Lisa K Torres; David A Berlin; Augustine M K Choi; Ilias I Siempos
Journal:  Chest       Date:  2018-10-22       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.